Metastatic Pancreatic Cancer - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 248 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Metastatic Pancreatic Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Pancreatic Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Pancreatic Cancer - Overview 9
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 10
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 11
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 15
Metastatic Pancreatic Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Metastatic Pancreatic Cancer - Products under Development by Companies 19
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 21
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 22
F. Hoffmann-La Roche Ltd. 22
AstraZeneca PLC 23
Eli Lilly and Company 24
GlaxoSmithKline plc 25
Gilead Sciences, Inc. 26
Merck & Co., Inc. 27
FibroGen, Inc. 28
Novartis AG 29
Pfizer Inc. 30
Silence Therapeutics plc 31
Celgene Corporation 32
Bayer AG 33
Incyte Corporation 34
Halozyme Therapeutics, Inc. 35
Momenta Pharmaceuticals, Inc. 36
Immunomedics, Inc. 37
Oncolytics Biotech Inc. 38
Synta Pharmaceuticals Corp. 39
NanoCarrier Co., Ltd. 40
Rexahn Pharmaceuticals, Inc. 41
Colby Pharmaceutical Company 42
INSYS Therapeutics, Inc. 43
OncoMed Pharmaceuticals, Inc. 44
Merrimack Pharmaceuticals, Inc. 45
Cornerstone Pharmaceuticals, Inc. 46
Pharma Mar, S.A. 47
Oncovir, Inc. 48
Cantex Pharmaceuticals, Inc. 49
Regulon Inc. 50
Fountain Biopharma Inc. 51
Oncozyme Pharma Inc. 52
AbbVie Inc. 53
Precision Biologics, Inc. 54
Metastatic Pancreatic Cancer - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 61
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
olaparib - Drug Profile 69
paclitaxel - Drug Profile 72
irinotecan sucrosofate liposomal - Drug Profile 75
yttrium Y 90 clivatuzumab tetraxetan - Drug Profile 77
cisplatin liposomal - Drug Profile 79
cisplatin - Drug Profile 81
nimotuzumab - Drug Profile 83
refametinib - Drug Profile 86
trametinib - Drug Profile 89
FG-3019 - Drug Profile 92
docetaxel - Drug Profile 94
CPI-613 - Drug Profile 96
paclitaxel - Drug Profile 98
ganetespib - Drug Profile 101
pelareorep - Drug Profile 105
RX-0201 - Drug Profile 109
irinotecan sucrosofate liposomal - Drug Profile 111
PGX-100 - Drug Profile 113
lurbinectedin - Drug Profile 115
ensituximab - Drug Profile 117
MK-2206 + selumetinib sulfate - Drug Profile 119
Atu-027 - Drug Profile 121
CIM-1 - Drug Profile 123
TL-118 - Drug Profile 124
LY-2090314 - Drug Profile 126
LY-2495655 - Drug Profile 127
PEGPH-20 - Drug Profile 128
necuparanib - Drug Profile 129
pentamidine isethionate - Drug Profile 130
veliparib - Drug Profile 132
galunisertib - Drug Profile 134
demcizumab - Drug Profile 136
LCL-161 - Drug Profile 139
bevacizumab - Drug Profile 141
galunisertib - Drug Profile 146
PD-0325901 + PF-05212384 - Drug Profile 148
HLA-A-2402 Restricted Antiangiogenic Peptide Vaccine - Drug Profile 149
INCB-39110 - Drug Profile 150
Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - Drug Profile 152
Poly-ICLC - Drug Profile 153
CPC-410 - Drug Profile 155
rottlerin - Drug Profile 156
FB-704A - Drug Profile 157
LY-2109761 - Drug Profile 158
Small Molecules for Oncology - Drug Profile 159
Manzamine A - Drug Profile 160
Metastatic Pancreatic Cancer - Recent Pipeline Updates 161
Metastatic Pancreatic Cancer - Dormant Projects 231
Metastatic Pancreatic Cancer - Discontinued Products 232
Metastatic Pancreatic Cancer - Product Development Milestones 233
Featured News & Press Releases 233
Appendix 244
Methodology 244
Coverage 244
Secondary Research 244
Primary Research 244
Expert Panel Validation 244
Contact Us 245
Disclaimer 245

List of Tables
Number of Products under Development for Metastatic Pancreatic Cancer, H2 2014 12
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Development by Companies, H2 2014 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2014 24
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 25
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca PLC, H2 2014 26
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2014 27
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 28
Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2014 29
Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2014 30
Metastatic Pancreatic Cancer - Pipeline by FibroGen, Inc., H2 2014 31
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H2 2014 32
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2014 33
Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics plc, H2 2014 34
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2014 35
Metastatic Pancreatic Cancer - Pipeline by Bayer AG, H2 2014 36
Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2014 37
Metastatic Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2014 38
Metastatic Pancreatic Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 39
Metastatic Pancreatic Cancer - Pipeline by Immunomedics, Inc., H2 2014 40
Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 41
Metastatic Pancreatic Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 42
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2014 43
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 44
Metastatic Pancreatic Cancer - Pipeline by Colby Pharmaceutical Company, H2 2014 45
Metastatic Pancreatic Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2014 46
Metastatic Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 47
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 48
Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 49
Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H2 2014 50
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2014 51
Metastatic Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2014 52
Metastatic Pancreatic Cancer - Pipeline by Regulon Inc., H2 2014 53
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2014 54
Metastatic Pancreatic Cancer - Pipeline by Oncozyme Pharma Inc., H2 2014 55
Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2014 56
Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2014 57
Assessment by Monotherapy Products, H2 2014 58
Assessment by Combination Products, H2 2014 59
Number of Products by Stage and Target, H2 2014 62
Number of Products by Stage and Mechanism of Action, H2 2014 66
Number of Products by Stage and Route of Administration, H2 2014 69
Number of Products by Stage and Molecule Type, H2 2014 71
Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H2 2014 164
Metastatic Pancreatic Cancer - Dormant Projects, H2 2014 234
Metastatic Pancreatic Cancer - Discontinued Products, H2 2014 235